Heterogeneity of Breast Cancer Associations with Common Genetic Variants in FGFR2 according to the Intrinsic Subtypes in Southern Han Chinese Women
Table 3
Association between the selected FGFR2 polymorphisms and breast cancer risk according to intrinsic subtype.
Genotype or allele
Controls (%)
All breast cancer cases ()
Luminal-A cases ()
Luminal-B cases ()
ER−HER2+ cases ()
Triple negative cases ()
()
Cases (%)
valuea
OR (95% CI)
Cases (%)
valuea
OR (95% CI)
Cases (%)
P valuea
OR (95% CI)
Cases (%)
P valuea
OR (95% CI)
Cases (%)
valuea
OR (95% CI)
rs1078806
T/T
448 (51.1%)
293 (48.3%)
—
1.00
123 (47.1%)
—
1.00
52 (46.0%)
—
1.00
61 (52.1%)
—
1.00
57 (49.1%)
—
1.00
C/T
352 (40.2%)
260 (42.8%)
6.5 × 10−1
1.16 (0.93–1.44)
117 (44.8%)
3.6 × 10−1
1.24 (0.92–1.66)
47 (41.6%)
3.9 × 10−1
1.17 (0.77–1.78)
48 (41.0%)
3.6 × 10−1
1.06 (0.70–1.59)
48 (41.4%)
9.5 × 10−1
1.11 (0.74–1.68)
C/C
76 (8.7%)
54 (8.9%)
7.6 × 10−1
1.06 (0.72–1.56)
21 (8.1%)
8.5 × 10−1
0.97 (0.57–1.65)
14 (12.4%)
1.8 × 10−1
1.55 (0.82–2.94)
8 (6.8%)
4.3 × 10−1
0.73 (0.33–1.60)
11 (9.5%)
7.3 × 10−1
1.13 (0.57–2.27)
trend
3.7 × 10−1
4.6 × 10−1
1.8 × 10−1
6.5 × 10−1
6.6 × 10−1
C/T + C/C
428 (48.9%)
314 (51.7%)
2.2 × 10−1
1.14 (0.92–1.41)
138 (52.9%)
2.2 × 10−1
1.19 (0.90–1.57)
61 (54.0%)
2.8 × 10−1
1.24 (0.84–1.84)
56 (47.9%)
9.7 × 10−1
0.99 (0.67–1.47)
59 (50.9%)
5.9 × 10−1
1.11 (0.75–1.65)
T
1248 (71.2%)
846 (69.7%)
—
1.00
363 (69.5%)
—
1.00
151 (66.8%)
—
1.00
170 (72.6%)
—
1.00
162 (69.8%)
—
1.00
C
504 (28.8%)
368 (30.3%)
3.5 × 10−1
1.08 (0.92–1.27)
159 (30.5%)
4.7 × 10−1
1.08 (0.87–1.34)
75 (33.2%)
1.8 × 10−1
1.22 (0.91–1.63)
64 (27.4%)
6.8 × 10−1
0.94 (0.69–1.27)
70 (30.2%)
6.1 × 10−1
1.08 (0.80–1.45)
rs2420946
C/C
323 (38.1%)
190 (31.5%)
—
1.00
—
1.00
35 (31.5%)
—
1.00
42 (35.9%)
—
1.00
40 (34.5%)
—
1.00
C/T
379 (44.8%)
297 (49.2%)
1.3 × 10−2
1.35 (1.07–1.71)
131 (50.6%)
8.0 × 10−3
1.55 (1.12–2.15)
50 (45.0%)
3.7 × 10−1
1.23 (0.78–1.95)
63 (53.9%)
2.1 × 10−1
1.31 (0.86–2.01)
53 (45.7%)
5.7 × 10−1
1.14 (0.73–1.76)
T/T
145 (17.1%)
116 (19.2%)
4.7 × 10−2
1.36 (1.00–1.85)
55 (21.2%)
1.1 × 10−2
1.69 (1.13–2.53)
26 (23.4%)
6.9 × 10−2
1.66 (0.96–2.86)
12 (10.3%)
1.9 × 10−1
0.64 (0.32–1.26)
23 (19.8%)
3.4 × 10−1
1.31 (0.75–2.27)
trend
2.1 × 10−2
5.6 × 10−3
7.6 × 10−2
5.0 × 10−1
3.7 × 10−1
C/T + T/T
524 (61.9%)
413 (68.5%)
7.2 × 10−3
1.35 (1.08–1.69)
186 (71.8%)
2.5 × 10−3
1.59 (1.17–2.16)
76 (68.5%)
1.6 × 10−1
1.35 (0.88–2.07)
75 (64.1%)
5.7 × 10−1
1.12 (0.75–1.69)
76 (65.5%)
4.2 × 10−1
1.18 (0.78–1.78)
C
1025 (60.5%)
677 (56.1%)
—
1.00
277 (52.5%)
—
1.00
120 (54.1%)
—
1.00
147 (62.8%)
—
1.00
133 (57.3%)
—
1.00
T
669 (39.5%)
529 (43.9%)
2.0 × 10−2
1.19 (1.03–1.39)
241 (46.5%)
5.0 × 10−3
1.32 (1.09–1.61)
102 (45.9%)
7.4 × 10−2
1.28 (0.98–1.68)
87 (37.2%)
5.4 × 10−1
0.92 (0.69–1.21)
99 (42.7%)
3.4 × 10−1
1.14 (0.87–1.50)
rs2981579
C/C
275 (31.4%)
153 (25.2%)
—
1.00
68 (25.9%)
—
1.00
22 (19.6%)
—
1.00
31 (26.5%)
—
1.00
32 (27.6%)
—
1.00
T/C
415 (47.4%)
297 (48.9%)
4.0 × 10−2
1.30 (1.01–1.67)
118 (44.9%)
3.8 × 10−1
1.16 (0.83–1.63)
59 (52.7%)
2.5 × 10−2
1.80 (1.08–3.00)
64 (54.7%)
1.7 × 10−1
1.38 (0.87–2.18)
56 (48.3%)
5.5 × 10−1
1.15 (0.72–1.83)
T/T
186 (21.2%)
158 (26%)
5.0 × 10−3
1.53 (1.14–2.05)
77 (29.3%)
7.0 × 10−3
1.68 (1.15–2.45)
31 (27.7%)
1.2 × 10−2
2.09 (1.17–3.73)
22 (18.8%)
9.1 × 10−1
1.03 (0.58–1.85)
28 (24.1%)
3.5 × 10−1
1.30 (0.75–2.24)
trend
3.8 × 10−3
7.8 × 10−3
1.2 × 10−2
7.3 × 10−1
3.5 × 10−1
T/C + T/T
601 (68.6%)
455 (74.8%)
8.1 × 10−3
1.37 (1.08–1.73)
195 (74.1%)
7.6 × 10−2
1.32 (0.97–1.81)
90 (80.4%)
7.4 × 10−3
1.89 (1.16–3.08)
86 (73.5%)
2.8 × 10−1
1.27 (0.82–1.97)
84 (72.4%)
4.1 × 10−1
1.20 (0.77–1.85)
C
965 (55.1%)
603 (49.6%)
—
1.00
254 (48.3%)
—
1.00
103 (46.0%)
—
1.00
126 (53.8%)
—
1.00
120 (51.7%)
—
1.00
T
787 (44.9%)
613 (50.4%)
4.0 × 10−3
1.24 (1.07–1.43)
272 (51.7%)
8.0 × 10−3
1.29 (1.07–1.57)
121 (54.0%)
1.1 × 10−2
1.43 (1.08–1.88)
108 (46.2%)
7.6 × 10−1
1.04 (0.79–1.37)
112 (48.3%)
3.4 × 10−1
1.14 (0.87–1.50)
rs2981582
C/C
370 (43.2%)
238 (39.2%)
—
1.00
89 (34%)
—
1.00
41 (36.6%)
—
1.00
57 (48.7%)
—
1.00
51 (44%)
—
1.00
T/C
375 (43.8%)
266 (43.8%)
3.6 × 10−1
1.11 (0.89–1.40)
119 (45.4%)
7.1 × 10−2
1.33 (0.98–1.82)
48 (42.9%)
4.9 × 10−1
1.16 (0.75–1.81)
52 (44.4%)
6.8 × 10−1
0.92 (0.61–1.38)
47 (40.5%)
6.5 × 10−1
0.91 (0.59–1.39)
T/T
111 (13.0%)
103 (17.0%)
3.3 × 10−2
1.41 (1.03–1.94)
54 (20.6%)
1.0 × 10−3
2.01 (1.35–3.01)
23 (20.5%)
3.3 × 10−2
1.83 (1.05–3.19)
8 (6.8%)
4.3 × 10−2
0.45 (0.21–0.98)
18 (15.5%)
6.6 × 10−1
1.14 (0.64–2.04)
trend
3.1 × 10−2
7.0 × 10−4
4.4 × 10−2
7.9 × 10−2
7.9 × 10−1
T/C + T/T
486 (56.8%)
369 (60.8%)
1.2 × 10−1
1.18 (0.95–1.47)
173 (66%)
6.7 × 10−3
1.49 (1.11–1.99)
71 (63.4%)
1.8 × 10−1
1.32 (0.88–1.99)
60 (51.3%)
2.8 × 10−1
0.81 (0.54–1.19)
65 (56.0%)
8.4 × 10−1
0.96 (0.65–1.42)
C
1115 (65.1%)
742 (61.1%)
—
1.00
297 (56.7%)
—
1.00
130 (58.0%)
—
1.00
166 (70.9%)
—
1.00
149 (64.2%)
—
1.00
T
597 (34.9%)
472 (38.9%)
4.0 × 10−2
1.17 (1.01–1.36)
227 (43.3%)
7.0 × 10−4
1.40 (1.15–1.71)
94 (42.0%)
5.0 × 10−2
1.32 (1.00–1.74)
68 (29.1%)
7.5 × 10−2
0.76 (0.57–1.03)
83 (35.8%)
8.6 × 10−1
1.03 (0.77–1.36)
Adjusted for age, age at first full-term pregnancy, menopausal status, and hormonal therapy status. Abbreviations: OR, odds ratio; CI, confidence interval; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2.
